News

The Phase I trial was a randomized, double-blind, ascending multiple-dose study in which all dose levels were well tolerated over 14 days and no dose limiting toxicities were

The JAK3 kinase is being evaluated for the treatment of immunological and inflammatory diseases. The JAK3 is selectively expressed in certain hematopoietic cells and is involved in T-cell

This patent, which allows exclusively through 2018, covers compositions of fusion proteins comprised of a human papillomavirus (HPV) antigen fused to a heat shock protein, as well as

The investigational new drug (IND) application contains a physical, chemical and structural analysis of safflower-produced insulin to a reference standard, results from 28-day sub-chronic toxicology studies in two

This double-blind, placebo-controlled, single-ascending dose (SAD) trial will determine the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in approximately 48 healthy male volunteers.

Under the terms of the agreement, Agilent will obtain from Roche a non-exclusive license to use, develop and sell products based on melting curve analysis. The melting curve

DoctorDirectory’s IncreaseRx utilizes web-based educational and promotional tactics to reach tens of thousands of interested prescribers with targeted sales and marketing messages. Essentially, IncreaseRx performs as a virtual

In addition to his ArunA leadership responsibilities, Mr Sharp has also been appointed to ArunA’s board of directors. Mr Sharp succeeds ArunA founder Steven Stice, who will remain

Barr’s abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic Sensipar product was received as acceptable for filing by the FDA on March 10,